End Taxpayer Funding of Gender Experimentation Act of 2023
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The End Taxpayer Funding of Gender Experimentation Act of 2023 (H.R. 3329) is a bill introduced in the 118th Congress aimed at prohibiting the use of federal funds for gender-related medical treatments or procedures often described as gender experimentation. The bill was referred to the House Subcommittee on Health but did not advance further and ultimately failed or expired. No official summary or full text is available, limiting detailed analysis of specific provisions. The bill falls under the health policy area and addresses federal funding restrictions related to gender-related healthcare services.
H.R. 3329 sought to end the use of taxpayer funds for gender-related medical treatments but did not progress beyond subcommittee referral and expired without enactment.
- The bill aims to prohibit federal funding for gender experimentation, a term used in the bill's title but not defined in available text.
- It was introduced in the House during the 118th Congress and referred to the Subcommittee on Health on December 17, 2024.
- The bill did not advance beyond referral and is listed as failed or expired as of December 20, 2024.
['Federal budget administrators potentially benefit from clarified restrictions on funding allocations.', 'Taxpayers who prefer limitations on federal spending in this area may be considered beneficiaries.', 'Healthcare providers and organizations not receiving federal funds for gender-related treatments may be indirectly affected.']
["Lack of available full text and official summary limits understanding of the bill's specific provisions and enforcement mechanisms.", "Potential challenges in defining and enforcing what constitutes 'gender experimentation' could complicate implementation.", "The bill's restrictions on funding may impact access to gender-related healthcare services for certain populations, raising policy tradeoffs.", 'Oversight responsibilities and authority for ensuring compliance with funding prohibitions are unclear without full text.']
The bill was introduced in the 118th Congress and referred to the House Subcommittee on Health but did not advance further. It addresses a contentious policy area involving federal funding for gender-related medical treatments. The absence of official summary and full text in the public record limits detailed legislative context. The bill's failure or expiration status indicates it did not receive sufficient support or priority for enactment during the session.
High concern review — 3 hidden impact flags detected
GovScope reviewed 3 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential reduction in federal healthcare funding allocations for gender-related treatments could lead to increased out-of-pocket costs for affected individuals.', 'Healthcare providers may alter service offerings or funding strategies in response to federal funding restrictions.', 'State and local governments or private insurers might experience increased demand to cover gender-related healthcare services if federal funding is restricted.']
The absence of an official summary and full bill text restricts comprehensive analysis and public transparency. The bill's title suggests significant policy changes regarding federal funding for gender-related healthcare, but undefined terminology and lack of detailed provisions pose challenges for oversight and enforcement evaluation. Monitoring similar future legislation should prioritize availability of complete legislative texts and clear definitions to support informed public discourse and accountability.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.